Is TIMP-1 immunoreactivity alone or in combination with other markers a predictor of benefit from anthracyclines in the BR9601 adjuvant breast cancer chemotherapy trial?

INTRODUCTION: Predictive cancer biomarkers to guide the right treatment to the right patient at the right time are strongly needed. The purpose of the present study was to validate prior results that tissue inhibitor of metalloproteinase 1 (TIMP-1) alone or in combination with either HER2 or TOP2A c...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
Main Authors: Munro, Alison F, Bartels, Annette, Balslev, Eva, Twelves, Christopher J, Cameron, David A, Brünner, Nils, Bartlett, John MS
Format: Artigo
Jezik:Inglês
Izdano: BioMed Central 2013
Teme:
Research Article
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC3672718/
https://ncbi.nlm.nih.gov/pubmed/23570501
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/bcr3411
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki